July 1, 2024
Announcement of new structure
Taisho Pharmaceutical Holdings Co., Ltd. (Head Office: Toshima-ku, Tokyo; CEO: Shigeru Uehara; "Taisho") announces the new structure.
1. About the Chief Executive Officer
| Post | Name |
| Chief Executive Officer | Shigeru Uehara |
2. Reasons for the Selection of the Chief Executive Officer
In response to changes in the environment surrounding the Company and the Group, we will take drastic and agile measures from a medium- to long-term perspective, and promptly and boldly implement management strategies that involve certain business risks.
3. Appointment of Other Officers
| Post | Name |
| Member of the Board (outside) | Takeshi Kunibe |
| Member of the Board (outside) | Makoto Matsuo |
| Audit & Supervisory Board Member | Kazuya Kameo |
| Audit & Supervisory Board Member | Takeshi Ikoma |
| Audit & Supervisory Board Member (outside) | Chushiro Aoi |
| Audit & Supervisory Board Member (outside) | Tsutomu Miyano |
4. Date of inauguration of the new structure
July 1, 2024
5. Supplement
On July 1, the Company absorbed and merged with Taisho Pharmaceutical Holdings Co., Ltd. and changed its trade name from Otemon Co., Ltd. to Taisho Pharmaceutical Holdings Co., Ltd.
6. Biography of theChief Executive Officer
| Name | Shigeru Uehara |
| Date of birth | May 5, 1976 |
| Birthplace | Tokyo |
|
Academic background |
Mar.2000 Graduated from Keio University Faculty of Commerce |
| Jun.2006 Graduated from Northwestern University, Kellogg | |
| Career | Apr. 2000 Joined Taisho Pharmaceutical Co., Ltd. |
| Apr. 2009 Executive Vice President and Head of Prescription Pharmaceutical Business Taisho Pharmaceutical Co., Ltd. | |
| Oct. 2011 Executive Vice President of the Company | |
| Jun. 2012 Chief Executive Officer (Representative) of Taisho Pharmaceutical Co., Ltd. (present) | |
| Jul. 2024 Chief Executive Officer of the Company（present） |